Idiopathic Pulmonary Fibrosis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market

Posted on
by

Idiopathic Pulmonary Fibrosis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market
Idiopathic Pulmonary Fibrosis Market
DelveInsight’s “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Idiopathic Pulmonary Fibrosis – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Idiopathic Pulmonary Fibrosis – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Idiopathic Pulmonary Fibrosis Market Report:

  • The total prevalent population of Idiopathic Pulmonary Fibrosis (IPF)  in the 7MM is expected to rise during the study period [2017–2030]. Estimates show the highest prevalent population of Idiopathic Pulmonary Fibrosis (IPF)  is in the United States followed by the UK. 
  • According to DelveInsight’s analysis, it has been observed that Moderate Idiopathic Pulmonary Fibrosis (IPF)  cases are more prominent in comparison to Mild and Severe cases across 7 MM.
  • Among the European 5 countries, the United Kingdom had the highest prevalent population of Idiopathic Pulmonary Fibrosis (IPF), followed by Italy and Germany. On the other hand, Spain had the lowest prevalent population of IPF. The highest rates of IPF in Europe are reported in the UK, with incidence rates between 4.6 and 8.65 per 100 000 people per year, and almost 6000 people diagnosed annually 

Key benefits of the report:

  1. Idiopathic Pulmonary Fibrosis market report covers a descriptive overview and comprehensive insight of the Idiopathic Pulmonary Fibrosis Epidemiology and Idiopathic Pulmonary Fibrosis  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Idiopathic Pulmonary Fibrosis market report provides insights on the current and emerging therapies.
  3. Idiopathic Pulmonary Fibrosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Idiopathic Pulmonary Fibrosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Idiopathic Pulmonary Fibrosis market.

Idiopathic Pulmonary Fibrosis Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial lung disease (ILD), characterized by fibrosis and worsening lung function, that primarily occurs in those 50 years and older. Various causes including genetic susceptibility, environmental risk factors, and exposures have been suggested in the literature. All of these cause repetitive micro-injury to the lung tissue and vasculature, which triggers a cascade of inflammatory response and fibrosis.

Idiopathic Pulmonary Fibrosis Market 

The dynamics of the Idiopathic Pulmonary Fibrosis market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as FibroGen, Kadmon Corporation, Promedior, Galapagos, MediciNova, and others during the forecasted period 2018-2030.

Idiopathic Pulmonary Fibrosis Pipeline Therapies and Key Companies 

  • Pamrevlumab: FibroGen
  • KD025: Kadmon Corporation
  • PRM-151: Promedior
  • GLPG1690: Galapagos
  • Tipelukast: MediciNova

Idiopathic Pulmonary Fibrosis Market Drivers 

  • The grant of special regulatory designations 
  • Several therapies in the pipeline from various companies 
  • An increase in the prevalence of fibrotic diseases

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance

5. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

6. Idiopathic Pulmonary Fibrosis Disease Background and Overview

7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Idiopathic Pulmonary Fibrosis 

9. Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices

10. Unmet Needs

11. Idiopathic Pulmonary Fibrosis Emerging Therapies

12. Idiopathic Pulmonary Fibrosis Market Outlook

13. Country-Wise Idiopathic Pulmonary Fibrosis Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Idiopathic Pulmonary Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Idiopathic Pulmonary Fibrosis Pipeline 

“Idiopathic Pulmonary Fibrosis Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Idiopathic Pulmonary Fibrosis market. A detailed picture of the Idiopathic Pulmonary Fibrosis pipeline landscape is provided, which includes the disease overview and Idiopathic Pulmonary Fibrosis treatment guidelines.

Idiopathic Pulmonary Fibrosis Epidemiology

DelveInsight’s ‘Idiopathic Pulmonary Fibrosis  Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Idiopathic Pulmonary Fibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/